

S&S Healthcare Holding Ltd. (Original name : Swissray Global Healthcare Holding Ltd.) (4198) Online Investor Conference

Alex Yeh, CEO December 22, 2021



Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by S&S Healthcare Holding Ltd. (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



Hochdorf, Switzerland

New Jersey, USA Wisconsin, USA

Taipei, Taiwan



Basic company information

Company Name	S&S Healthcare Holding Limited (Original name: Swissray Global Healthcare Holding Limitied)
Company Establishment	January 07, 2013
Chairman	Pei-Lin Lee
CEO	Alex. Yeh
C00	Peter Lee
Industry	Biotechnology and Medical Care
Company establishment address	Taipei City
Paid-in Capital	NTD\$805,400,000 (80,540thousand shares (Contains private common stock 38 million shares))





Operational and Future Outlook



5





Operational and Future Outlook



SOARMED Co., Ltd.



SOARMED Co., Ltd..

Veterinary Medical Device

1. Market Overview-Taiwan

(1)Approximately 1,600~1,800 Veterinary Clinics
(2)Current business model : none specialize orientate •

2. Market Strategy

(1)Existing clinics' medical devices upgrade
(2)Expanding sales for newly open clinics •

3. Future Outlook

(1)R&D: Anesthesia device upgrade \ ICU specialize device
(2)Group source integration \ expanding product profolic
(3)Distribution net work intergration for Taiwan' s veterinary medical device market



SRA Pet Supplies

SRA - Pet Supplies BU



1. Market Overview-Taiwan

(1)Major pet supplies industry : food $\$ supplies $\$ service \circ

(2)Pet supplies BU focus: Pet food > Pet supplies > Pet service

- Pet food : Dry food \ canned food \ snacks \ nutritional supplements and healthcare food \circ
- ♦ Pet supplies : Costumes \, general supplies \, toys \, food and water accessories \,
- Pet service : Medical treatment · hotel · grooming · training · insurance and mortuary services ·



SRA - Pet Supplies BU



2. Market Prospect

- (1)According to marketing research, Taiwan's pet food market has CGR of 2.9% in 2021 and growing \circ
- (2)Market distribution of pet food : Dry food 48%, canned food 26%, snacks
 11%, prescription food 9.1%, liquid food 4%, organic food 1.8% °
- (3)Local vs Import ratio; General Pet food 3:7 Healthcare Pet food :
 2:8
- (4)In 2022 the deployment and planning of emerging pet industry will be focused on healthcare food • The global market for pet's healthcare food is estimate to have 7.6B USD with annual CGR of 4.83% •

3. Future Outlook

a.Join venture with other pet food manufacture for new pet healthcare products $\ \circ$

- b. Group source integration \cdot channel and healthcare service expansion \circ
- c.Market preparation for SEA $\$ China and Japan \circ



Shin Shin Healthcare Ltd.



Shin Shin Healthcare

Target

Top 10 medical mask supplier in Taiwan"

• Certification for Taiwan medical mask

• Supply chain for top 10 hospital network

• Establish brand image

2022 Outlook:

2022 estimate revenue distribution: 70% local, 30% international

- Group source intergration
- CE & FDA certification
- Production optimization and implementation of ERP and e-commerce platform.
- · Local and international trade show awareness
- Long term sale' contracts

Target Strategy: Long term and stable supply contracts

- Functional over short term popularity
- Realization of Market Strategy
- Expand product portfolio and optimize production equipments
- Innovation, Creativity, Creation



Market Strategy





Swissray Asia Ltd. Cosmeceuticals

SRA-Cosmeceuticals BU



Market Channels

Cosmed-Face mask
 Watsons
 Poya-Medical masks
 Chain convenience
 store –seasonal products



Strategy

- 1.Exclusive right to maintain pricing right for max product margin
- 2.Multiple brands/products with exclusive contract for physical chain store to minimize channel expenses
- 3.Market and channel demand orientate

Products Deployment

- 1.Create need of perfume and fragrance product
- 2.Fulfill the gap of market with seasonal and
- cosmetic products
- 3.Own brand-personal care products
- 4.Healthcare food- Weight loss and beauty drinks

Sale Strategy

- 1.Marketing and promoting with well known care product brand
- 2.Brand distribution-Virtual channel authorization
- 3.Sales Consultation-Rapid channel distribution



Swissray Asia Ltd. Ultrasound



SRA-Ultrasound

Product Strategy

- New Model
 - uREzpocus Cardio for TFDA approval
 - uREzpocus 710 Series 510k update
- Market Differentiation
 - uREzpocus Thermal printer solution
 - uREzpocus Off-site inspection
 - uREzpocus Focus treatment
 - uREzpocus Telemedicine solution

Channel Strategy

- Channel Type(physical and virtual):
 - Virtual: Amazon

 e-com
 - Distributor: Northen/central/Southen regional distributor
 - Niche Channel:
 - Cardiology Surgical
 - ER \ ICU \ Surgery
 - Veterinary Clinics
- Channel Structure
 - Flat : minimum layers
 - Niche: minimum competitors
 - Service orientate : Collaboration with professional academia and users



Swissray Asia Ltd. Optical Care & BoneHealth

SRA-Optical Care BU



- 1) Product approval for Taiwan
 - Completion of clinical trail •
 - ◆ Estimate by Q2 2022 °
- 2) Sales channel for Taiwan
 - ◆ Establish Hospital and clinics network ∘
 - Collaboration with current major ophthalmology distributors for market penetration °
 - Optimize sale margin by direct sale though ophthalmology clinics groups °

3) Product portfolio

- Portfolio expansion by collaboration/OEM with current contact lens designer such as RGP and scleral contact lens
- ◆ Industry and academia collaboration for next generation product 。
- 4) China Market

Preparation for China's production registration •

SRA- Bone Health Norland BU

- 1) Relocation of manufacture facility
 - igoplus Transfer inventory and stock from US to Taiwan in 2022 \circ
 - Complete production set up in Taiwan •
- 2) Establish supply chain net work in Taiwan
 - ◆ Minimize cost to increase sales margin ∘
- 3) Certification for new manufacture facility
 - ISO 13485 and GMP certification •
 - igoplus 510k transfer to facility in Taiwan $\,\circ\,$
- 4) Improving sales channels
 - Strengthen distribution channels for Asia market •
 - Increase price competitiveness for Asia market •
 - Continuation marketing for US sport market and maintain service revenue •





Q&A



Thank you for your time.